test header

Cell Therapy

Hematology

Salt Lake City

Poster

Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Irtiza N. Sheikh, DO, Krish Patel, MD, Miguel-Angel Perales, MD, Ran Reshef, MD, MSc, Matthew Frigault, MD, Matthew Lunning, DO, FACP, Jennifer L. Crombie, MD, Iris Isufi, MD, Marcelo C. Pasquini, MD, MS, David Bernasconi, MSc, Prachi Ghodke, MSc, Debasmita Roy, PhD, Bradley D. Hunter, MD, MPH, Sairah Ahmed, MD

Poster

Optimization of Remote Patient Monitoring in the Outpatient Setting after Lisocabtagene Maraleucel (Liso-cel): Alarm Patterns and Hospitalization in a Multicenter Cohort

Minoo Battiwalla, Gita Nadimpalli, Shanna Arnold Egloff, Casey Martin, Matt Wilkes, Nosha Farhadfar, Uttam Rao, Michael Tees, Krish Patel, Laura Daniel, Fei Fei Liu, Afraim Botros, Lena Charafi, Betsy Blunk, Max Henkel, Meredith Mattlin, Debasmita Roy, Nicole Zahradka, Priya Amin, Jinender Kumar, Tonya Cox, Rocky Billups, and Navneet Majhail

Oral

Real-World Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-cel) and Axicabtagene Ciloleucel (Axi-cel) in Patients with R/R Large B-Cell Lymphoma (LBCL) in the Second-Line (2L) Treatment Setting

Nathan Denlinger, DO, MS, Matthew Schwede, MD, Samuel Yamshon, MD, Joanna Rhodes, MD, Jason Romancik, MD, Farah Toron, MSc, James Roose, MA, Ahmed Sawas, MD, Matt Bye, MPH, Robert Braun, MD, MBA, Debasmita Roy, PhD, Fei Fei Liu, GDCE, MBA, Narendranath Epperla, MD, MS, Marco Davila, MD, PhD

Poster

Real-World Evaluation of Health Care Resource Utilization, Clinical Effectiveness, and Safety of Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) Administered in the Outpatient (OP) Setting for R/R Large B-Cell Lymphoma (LBCL)

Sagar S. Patel, MD, Elise A. Chong, MD, Farah Toron, MSc, Fei Fei Liu, GDCE, MBA, Fangyi Gu, ScD, John H. Baird, MD, Sameh Gaballa, MD

Oral

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Sairah Ahmed, MD, Alejandro Martín García-Sancho, MD, PhD, Juan Luis Reguera Ortega, MD, Guillaume Cartron, MD, PhD, Aaron P. Rapoport, MD, Koji Izutsu, MD, PhD, Hervé Ghesquieres, MD, PhD, Hideki Goto, MD, PhD, Jeremy S. Abramson, MD, MMSc, Peter Borchmann, MD, Ulrich Jäger, MD, Manali Kamdar, MD, MBBS, Martin Dreyling, MD, Merav Bar, MD, Maria Strocchia, PharmD, PhD, Martina Raggi, PhD, Luciana Bueno, MD, Jessica Papuga, PhD, Silvia Colicino, PhD, Franck Morschhauser, MD, PhD

Poster

CAR T Cell Therapy Referral Patterns and Characteristics of Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in the United States

Mazyar Shadman, MD, MPH, Fei Fei Liu, GDCE, MBA, Christine Fu, PhD, Michael Cantrell, PhD, Amit Goyal, MBA, Dwaipayan Mukherjee, MBA, Tara Graff, DO, MS

Oral

Clinical Outcomes From the Pooled Safety Analysis of CD19 NEX-T (BMS-986353), a Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, in Severe Refractory Autoimmune Diseases: Results From Phase 1 Breakfree Studies

Ran Reshef, Jacques Azzi, Ernesto Ayala, Mohamad Cherry, Richard Nash, Marie Luise Hütter-Krönke, Paolo Caimi, Bastian von Tresckow, Swathi Namburi, Francisco Pérez-Miralles, Armin Ghobadi, Valentin Ortiz-Maldonado, Breogán Rodriguez-Acevedo, Alisha Desai, Lisa Kelly, Alexis Melton, Brandon Law, Burhan Chaudhry, Rafael Sarmiento, Lingyun Lyu, Griff McTume, Takafumi Ide, Praneeth Jarugula, Melissa Harnois, Jerill Thorpe, Ashley Koegel, Fabian Müller

Oral

KarMMa-3 Subgroup Analysis in Older Patients with relapsed/refractory Multiple Myeloma Treated with Idecabtagene Vicleucel

Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Shinsuke Iida, Sophie Hello, Devender Dhanda, Prachi Ghodke, Martina Raggi, Roland Marion Gallois, Jaclyn Davis, Paula Rodriguez-Otero

Poster

Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)

Ciara L. Freeman, Nisha Joseph, Sarah M. Larson, Omar Nadeem, Nikhil Munshi, Shinsuke Iida, Sham Mailankody, Paola Neri, Tara Gregory, Julia Piasecki, Safiyyah Ziyad, Hongxiang Hu, Svenja Groeneveld, Sarah Johnston, Timothy Pulham, Sandy W. Wong, Jaclyn Davis, Susan Bal, Anupama Kumar, Krina Patel

Poster

Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

Eyal Lebel, Ahmed Abdulgawad, Stefania Bramanti, Gonzalo Garate, Phoebe Joy Ho, Mikko Keränen, Yael Cohen, Maja Vase, Amit Khot, Ida Bruun Kristensen, Richard LeBlanc, Cindy Lee, Wojciech Legiec, Hila Magen, María-Victoria Mateos, Danielle Oh, Ludek Pour, Natalia Schutz, Alexandros Spyridonidis, Katja Weisel, Jan Zaucha, Sarah Larson, Asya Varshavsky-Yanovsky, Kimberly Grazioli, Debashree Basudhar, Hongxiang Hu, Ya Meng, Lamis Eldjerou, Susan Bal, Simon Harrison, Rakesh Popat, Marc Raab, Paula Rodriguez-Otero

Poster

Real-World Outcomes in Older Adults With Triple-Class Exposed Multiple Myeloma

Surbhi Sidana, Devender S. Dhanda, Sophie Hello, Jiaqi Fang, Gaurav Deshpande, Tao Gu, Luciano J. Costa